Azenta

Azenta, Inc. is a provider of life sciences sample exploration and management solutions for the life sciences market. It operates through the Life Sciences Products and Life Sciences Services segments. The Life Sciences Products segment is involved in automated cold storage solutions for biological and chemical compound samples. The Life Sciences Services segment focuses on the solutions addressing the many needs of customers in the area of genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development markets. The company was founded in 1978 and is headquartered in Burlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Azenta (AZTA) reports robust Q1 earnings, eyes strategic investments

Azenta's Q1 results showcase strong revenue growth and strategic acquisitions, positioning the company for future success. While facing challenges in certain segments, the focus on investments and efficiencies presents opportunities for growth and margin improvement.

Azenta reports mixed Q2 results, focuses on growth initiatives

Azenta's Q2 2023 performance was mixed, with challenges in B Medical impacting revenue but Services business showing resilience and genomics revenue rebounding positively.
Strategic acquisitions, cost actions, and a realignment initiative aim to enhance profitability and drive growth, with a focus on accelerating organic growth and expanding Services business.
Despite margin decreases and revenue challenges, Azenta remains focused on growth initiatives, addressing concerns about distractions and emphasizing opportunities for expansion and profitability.
Management's outlook includes revised revenue guidance, adjusted EBITDA margin expectations, and a commitment to driving profitability through growth initiatives and cost actions.

Azenta reports solid Q3 earnings, eyes growth in China

Azenta's Q3 performance showcased positive financial indicators, with notable growth in key segments and a focus on cost reduction initiatives.
While facing challenges in the Products segment and market share determination, the company remains optimistic about growth opportunities in China and key service offerings.
With a strong focus on sales, marketing, and cost reduction, Azenta aims to sustain its growth trajectory and enhance profitability in the future.

Azenta reports robust Q4 earnings, eyes growth opportunities in 2024

Azenta's Q4 performance was strong, with positive outlook for fiscal 2024 and a commitment to share repurchase.
While facing challenges in gross margins, the company sees opportunities in organic growth and margin expansion.
Strengthening Cell and Gene Therapy business and operational improvements are key focus areas for future growth.
Overall, Azenta remains confident in its ability to outperform the market and enhance profitability.

Azenta reports Q1 revenue decline but sees growth opportunities ahead

Azenta's Q1 performance showed mixed results with revenue decline but growth in key segments. The company remains focused on maintaining guidance and balancing revenue throughout the year.
While facing challenges in B Medical revenue and market dynamics, Azenta has opportunities in sample retrieval programs and financial performance improvements.
Overall, Azenta's strategic focus on key segments and opportunities for growth position the company well for future success, despite current challenges and market conditions.

Azenta reports solid Q2 earnings, eyes growth in China

Azenta's Q2 performance showed revenue growth and improved margins despite challenges.
The company's strengths lie in strong segment growth and market outperformance in China.
Challenges include lower guidance for B Medical and softness in the Instruments segment.
Opportunities arise from pursuing Ascend 2026 plan, NGS shift, and China market growth.

Azenta reports strong Q3 performance and operational profitability growth

Azenta's Q3 results reflect a positive trajectory with revenue growth and improved profitability.
Strategic focus on key segments and the Ascend 2026 program are driving operational efficiency and margin expansion.
While challenges exist in certain segments, opportunities for growth and optimization present a promising outlook for Azenta.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHELMSFORD, Mass., Feb. 1, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has completed the previously announced sale of the company's Semiconductor Solutions Group business (or "automation business") to Thomas H.

Azenta Life Sciences Completes Sale of Semiconductor Solutions Group Business to Thomas H. Lee Partners

CHELMSFORD, Mass, Jan. 24, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal 2022 first quarter earnings which ended on December 31, 2021 on Tuesday, February 8, 2022 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, February 8, 2022 at 4:30 p.m.

Azenta Life Sciences Announces Fiscal 2022 First Quarter Earnings Conference Call and Webcast

Brooks (AZTA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Brooks (AZTA) Loses 7.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sendas Distribuidora SA

Blackbaud

Surgery Partners

Investors who can spot the overpriced stocks and shun them at the right time are the ones likely to make a profit. SGRY, ASAI, BLKB and AZTA are a few toxic stocks that you should disown right away.

Save Your Portfolio by Getting Rid of These 4 Toxic Stocks

Upcoming divestiture of the semiconductor business creates a catalyst for Azenta as a company laser-focused on the life sciences industry. Impending a $2.6B cash infusion from the sale of the semiconductor business will enable the company to accelerate growth through R&D and M&A.

Azenta: Hyper-Focus On Life Sciences Will Unleash Growth But Wait For A Pullback

Brooks Automation

CHELMSFORD, Mass., Jan. 6, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has appointed Matthew McManus Chief Operating Officer effective January 17th.

Azenta Life Sciences Names Matthew McManus Chief Operating Officer

CHELMSFORD, Mass., Dec. 21, 2021 /PRNewswire/ -- Azenta, Inc. (Nasdaq:AZTA) announced today that company management will participate in the 40th Annual J.P.

Azenta Life Sciences to Participate in the 40th Annual J.P. Morgan Conference

CHELMSFORD, Mass., Dec. 20, 2021 /PRNewswire/ -- Azenta, Inc. (Nasdaq:AZTA) announced today that company management will participate in the 24th Annual Needham Virtual Growth Conference on Monday, January 10, 2022 which includes a webcast beginning at 1:15 p.m.

Azenta Life Sciences to Participate in the 24th Annual Needham Virtual Growth Conference

CHELMSFORD, Mass., Dec. 1, 2021 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or the "Company") announced today that it has completed its previously announced corporate name change from "Brooks Automation, Inc." to "Azenta, Inc." In conjunction with the corporate name change, the Company will begin trading on the Nasdaq Global Select Market under the new ticker symbol, AZTA, effective at the open of market trading on December 1, 2021.

Azenta, Inc. (Nasdaq: AZTA) Announces Completion of Corporate Name and Stock Ticker Symbol Change from Brooks Automation, Inc. (Nasdaq: BRKS)

News for Azenta Stock (AZTA)